Could a fixed T-Cell dose make stem cell transplants safer?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients must be ≥19 years of age. 2. Patients must meet all the UAB diagnosis and disease status criteria for clinical appropriateness for myeloablative allo HSCT derived from ASBMT and NCCN guidelines. 3. Patients must have a 10/10 HLA matched sibling (excluding identical twin). All donors will be evaluated for eligibility and suitability per standard of care according FACT and NMDP guidelines. 4. Adequate organ function: All organ function testing should be done within 28 days of study registration. 5. Cardiac: Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA (Multi Gated Acquisition) scan or echocardiogram. 6. Pulmonary: FEV1 (Forced expiratory volume in 1 second) and FVC (Forced vital capacity) ≥ 50% predicted, DLCO (alveolar diffusion capacity for carbon monoxide) (corrected for hemoglobin) ≥ 50% of predicted. 7. Renal: The estimated creatinine clearance (CrCl) must be equal or greater than 60 mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula 8. Performance status: Karnofsky ≥ 70% 9. Hepatic (values to be less than what is considered grade II toxicity per the CTCAE (common terminology criteria for adverse events) Exclusion criteria 1. Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection by imaging studies such as chest CT scan within 14 days of registration. 2. HIV positive patients. 3. Prior autologous or allogeneic transplantation for any disease. 4. Scheduled to receive non-myeloablative or reduced intensity conditioning regimen. 5. High Risk Features associated with increased relapse risk or poor outcomes: 1. AML/ALL: with Bi-phenotypic features 2. AML: Refractory to Induction and salvage therapy 3. ALL: Refractory to Induction and salvage therapy 4. CML: Active blast crisis 5. HL: Disease refractory to chemotherapy or targeted therapy 6. NHL: Disease refractory to chemotherapy or targeted therapy